Rx Product News (April 2017)

Pharmacy Times, April 2017 Respiratory Health, Volume 83, Issue 4

Read about the new Rx products featured in April.

MARKETED BY: Valeant Pharmaceuticals International

INDICATION: The FDA has approved Siliq (brodalumab) injection for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond, or have lost response, to other systemic therapies.

DOSAGE FORM: Subcutaneous injection: 210 mg

FOR MORE INFORMATION: valeant.com

SPIRIVA RESPIMAT MARKETED BY: Boehringer Ingelheim

INDICATION: The FDA has expanded the indicated for the approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in individuals 6 years and older.

DOSAGE FORM: Oral inhalation: 1.25 mcg

FOR MORE INFORMATION: spiriva.com

PARSABIV MARKETED BY: Amgen

INDICATION: The FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on hemodialysis.

DOSAGE FORM: Injection: 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL

FOR MORE INFORMATION: amgen.com

TRULICITY

MARKETED BY: Eli Lilly

INDICATION: The FDA approved Eli Lilly’s updated label for its type 2 diabetes drug, Trulicity (dulaglutide), to include use in combination with basal insulin for adults with type 2 diabetes. The FDA included the changes to the approved product labeling to reflect this important information for prescribers.

DOSAGE FORM: Injection: 0.75 and 1.5 mg

FOR MORE INFORMATION: trulicity.com